Business Wire

AOP-ORPHAN

15.11.2021 13:26:05 CET | Business Wire | Press release

Share
BESREMi® (Ropeginterferon alfa-2b) approved by the US FDA

In 2009, AOP Orphan in-licensed the exclusive rights for clinical development and commercialization of Ropeginterferon alfa-2b in Polycythaemia Vera (PV), a rare disease, and other myeloproliferative neoplasms (MPNs) for European, Commonwealth of Independent States (CIS), and Middle Eastern markets. Based on a pivotal study development program, which included the studies PEGINVERA, PROUD-PV and CONTINUATION-PV the European Medicines Agency (EMA) authorized BESREMi® for the treatment of PV in February 2019. The whole clinical development program was designed and conducted by AOP Orphan in Europe.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211115005741/en/

PharmaEssentia Corp., AOP Orphan’s licensor, subsequently submitted the clinical data generated in the clinical development program for marketing authorisation of BESREMi® by the FDA in the United States. On March 12, 2021, according to PharmaEssentia, the FDA issued a Complete Response Letter for BESREMi® (Ropeginterferon alfa-2b) confirming the safety and efficacy of BESREMi® in compliance with FDA regulations. Now, after PharmaEssentia’s manufacturing sites in Taiwan have successfully passed the FDA’s GMP pre-approval inspection in September 2021, the FDA approved BESREMi® for sale in the United States.

“FDA’s confirmation of BESREMi®’s safety and efficacy, based on AOP Orphan’s clinical study program and scientific knowledge, attests to the quality of work at our company" says Dr. Rudolf Widmann , Member of the Governing Board of AOP Orphan International. "We are extremely happy that now patients in the US have access for treating this rare blood cancer disease. This is the first of AOP Orphan’s ambitious projects to get medicinal products for rare and special diseases approved in the US. This achievement speaks not only to the scientific expertise and clinical development know-how of AOP Orphan, but also supports our company strategy to make drugs for rare and special diseases available worldwide."

Clinical studies conducted by AOP Orphan

Ropeginterferon alfa-2b is a specifically modified pegylated Interferon alpha 2b invented by PharmaEssentia’s CEO KC Lin.

The application of this third-generation interferon to the treatment of PV was invented by Dr. Rudolf Widmann of AOP Orphan: The company has continually invested in its hematology and drug development know-how to get an injection pen for patients’ at-home self-administration approved. Several clinical studies have been conducted by the company leading to a successful marketing authorization of BESREMi® for the treatment of Polycythaemia Vera in the EU in February 2019, in Switzerland and in Taiwan in 2020, in Israel and Korea in 2021.

Besides achieving high rates of complete hematologic responses including freedom of phlebotomy in 8 out of 10 patients, BESREMi® offers the possibility of disease modification and eventually operational cure in a subset of patients. This is exemplified by a decrease of mutant JAK2 allele burden (the disease-causing oncogene) from 37.3% at baseline to 7.3% in patients receiving Ropeginterferon alfa-2b, while an increase from 38.1% to 42.6% in the control group receiving hydroxyurea/best available therapy was observed (p<0.0001).1

Polycythaemia Vera patients in approximately 20 European countries are already being treated with Ropeginterferon alfa-2b. AOP Orphan is continuously working on increasing access for many more patients and continues the clinical development of BESREMi®.

About BESREMi®
BESREMi® is a long-acting, mono-pegylated proline interferon (ATC L03AB15). Its unique pharmacokinetic properties offer a new level of tolerability. BESREMi® is designed to be conveniently self-administered subcutaneously with a pen once every two weeks, or monthly after stabilization of hematological parameters. This treatment schedule is expected to lead to overall better safety, tolerability and adherence compared to conventional pegylated interferons. Ropeginterferon alfa-2b was discovered by PharmaEssentia, a long-term partner of AOP Orphan.

For the EMA Summary of Product Characteristics please visit: https://www.ema.europa.eu/en/documents/product-information/besremi-epar-product-information_en.pdf

AOP Orphan Pharmaceuticals GmbH (AOP Orphan) is an international pharmaceutical company with its headquarters in Vienna and a focus on rare and special diseases. Over the past 25 years, the company has become an established provider of integrated therapy solutions from its headquarters in Vienna. This development has been made possible by a continually high level of investment in research and development on the one hand and a highly consistent and pragmatic orientation towards the needs of all our stakeholders on the other - especially the patients and their families but also the doctors and care professionals treating them.

1 https://ash.confex.com/ash/2020/webprogram/Paper136973.html

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

UPS Announces Agreement to Acquire Smartways Logistics17.11.2026 22:00:00 CET | Press release

Planned acquisition enhances how UPS serves time-critical complex healthcare needs across Asia Pacific region UPS (NYSE: UPS) today announced it has entered into an agreement to acquire Smartways Logistics (Smartways), a healthcare logistics provider serving Australia and New Zealand. Once completed, the acquisition will enhance UPS Healthcare’s time-critical transportation capabilities in the region. Smartways enables healthcare customers to move critical shipments quickly and reliably, with specialized services for life sciences, medical devices, clinical trials and radiopharmaceuticals. The acquisition will build on UPS Healthcare’s ability to deliver for customers with urgent and complex logistics needs, while expanding the services available in Australia, New Zealand and the Asia Pacific region. “As healthcare becomes increasingly complex, logistics plays an even more critical role. It takes specialized capabilities and precision at every step to help vital healthcare products rea

Spatial Announces Release 2027 1.0 with New Enhancements Across CAD Modeling, Interoperability, Data Preparation, and Meshing17.11.2026 20:10:00 CET | Press release

Spatial Corp., the leading software development kit provider for design, manufacturing and engineering solutions and a subsidiary of Dassault Systèmes, today announced the availability of its 2027 1.0 Release. This latest release introduces new capabilities and enhancements across Spatial's 3D ACIS Modeler, CGM Modeler, 3D InterOp, Data Prep and CSM/CVM product lines. Designed to improve efficiency, flexibility and robustness across CAD modeling, interoperability, data preparation and simulation workflows, the release delivers enhanced geometry processing, expanded modeling capabilities, improved CAD translation and advances in mesh generation for a better workflow coverage. 3D ACIS Modeler Enhanced Blending (Filleting) The 3D ACIS Modeler introduces support for asymmetric fixed-width blends with a conic cross-section, providing users with finer control over smooth transitions between edges. This enhancement builds on the symmetric fixed-width blend with a conic cross-section capabilit

Global EV Alliance Survey: EV Drivers Identify Myths and Misconceptions as the Biggest Barrier to Adoption17.11.2026 19:00:00 CET | Press release

Myths and misconceptions about electric cars, from battery lifespan and fire risk to grid collapse, are the biggest barrier to EV adoption, according to respondents to the annual Global EV Driver Survey. The 2026 survey draws on responses from more than 29,500 EV drivers across 34 countries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117539716/en/ MYTHS. Battery lifespan (72%), fire risk (58%) and grid collapse (45%) top the list of EV myths reported by respondents to the 2026 Global EV Driver Survey, which gathered responses from more than 29,500 EV drivers across 34 countries. “The EV transition is not just an infrastructure or affordability challenge. It is also an information challenge. Outdated information and misconceptions continue to influence decisions long after the technology has moved on,” says Ellen Hiep, from the Steering Committee of the Global EV Alliance (GEVA). Myths the greatest barrier Asked to ide

TreeFrog Therapeutics Appoints James Sterling as Chief Financial Officer17.11.2026 18:04:00 CET | Press release

Seasoned biotech CFO with gene therapy, diagnostics, IPO and Wall Street experience joins the executive leadership team TreeFrog Therapeutics, a biotechnology company developing scalable cell therapies built on its proprietary C-Stem™ technology, today announced the appointment of James Sterling as Chief Financial Officer, effective November 1, 2026. James joins TreeFrog’s executive leadership team and reports to Mark Rothera, President and Chief Executive Officer. He oversees finance, investor relations and corporate development as the company enters its next phase of growth. “I am delighted to welcome James to TreeFrog. James brings a valuable combination of biotech CFO and Wall Street experience that supports our ambitions to develop TreeFrog into a key enabling partner and drug developer in the regenerative medicines field,” said Mark Rothera, President and Chief Executive Officer of TreeFrog Therapeutics. James contributes deep experience in corporate finance, capital markets and

Visa Report: AI-Enabled Fraud and Third-Party Attacks Are Scaling Worldwide17.11.2026 16:40:00 CET | Press release

Third-party incidents surged 62%, while Visa Scam Disruption identified more than $1.4 billion in potential fraud Fraud is becoming more automated, targeted and global as criminals use AI to exploit weak points across the payments ecosystem and target third-party providers that can provide access to multiple downstream payment organizations, according to the Visa (NYSE: V) Fall 2026 Biannual Threats Report released today during International Fraud Awareness Week. Developed by Visa Payment Ecosystem Risk and Control (PERC), the report examines threat activity observed between January and June 2026 and finds that AI is not creating entirely new categories of fraud. Instead, it is helping criminals that execute existing attacks faster, at greater scale, and with greater precision, while increasingly targeting third-party providers that can provide access to multiple downstream organizations at once. Although attack volumes increased in several areas, the report also found evidence that co

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye